

Date: January 22, 2014

Page: 1/2

BIOTRONIK SE & Co. KG  
Woermannkehre 1  
12359 Berlin  
Tel +49 (0) 30 68905-1466  
Fax +49 (0) 30 68905-961466  
www.biotronik.com

## Vascular Intervention

### **BIOTRONIK Announces Europe-wide Release of Passeo-18 Lux Peripheral Vascular Drug Releasing Balloon**

#### **BIOLUX P-I Study Confirms Clinical Efficacy of Innovative Product to Treat de Novo and Restenotic Femoropopliteal Lesions**

BUELACH, Switzerland, January 22, 2014 – [BIOTRONIK](#), a leading manufacturer of cardiovascular devices, today announced the release of its Passeo-18 Lux Drug Releasing Balloon (DRB) in all countries accepting CE mark, following recent CE approval.

The Passeo-18 Lux DRB catheter has already shown clinical efficacy in the [BIOLUX P-I study](#). Data collected at 6-month and 12-month intervals demonstrated that patients treated with Passeo-18 Lux were less likely to require treatment again.

BIOLUX P-I is a randomized, controlled study investigating the safety and performance of Passeo-18 Lux (n=30) versus an uncoated Passeo-18 PTA catheter (n=30) in the treatment of lesions in the femoropopliteal segment of up to 200 mm in length. The primary endpoint is late lumen loss in the Passeo-18 Lux arm versus the uncoated PTA (percutaneous transluminal angioplasty) catheter arm. Secondary endpoints include the Target Lesion Revascularization (TLR) rate and the Rutherford classification. The study enrolled patients at six centers in Germany and Austria.

Six-month primary endpoint data, evaluated by an independent core lab, previously documented significantly reduced angiographic late lumen loss (LLL) ( $p=0.038^*$ ) in the Passeo-18 Lux arm ( $LLL= 0.55 \pm 0.73$  mm) versus the uncoated PTA catheter ( $LLL= 1.07 \pm 1.01$  mm). Binary restenosis was also reduced ( $p=0.048^*$ ) in the Passeo-18 Lux arm versus the uncoated PTA catheter (11.5 percent vs. 34.6 percent respectively).

At 12 months, Kaplan-Meier estimates demonstrated a freedom from TLR rate of 84.6 percent for patients treated with Passeo-18 Lux versus 58.3 percent of patients treated with an uncoated PTA catheter ( $p=0.064$ ). Furthermore, patients receiving treatment with Passeo-18 Lux demonstrated greater improvement in Rutherford classification compared to baseline (72 percent) versus those receiving treatment with PTA (65.2 percent).

“Passeo-18 Lux has demonstrated excellent clinical results and supports our growing confidence in DRBs”, commented [Professor Dierk Scheinert](#), Chief Clinical Investigator of BIOLUX P-I and Department Head, Cardiac Center, [Park Hospital, Leipzig](#), Germany. “It is very deliverable and easy to use compared with other technologies and treatment options for these demanding vessels.”

Passeo-18 Lux is a novel combination device for treating de novo and restenotic femoropopliteal lesions. Its design is based on that of the proven Passeo-18 PTA catheter, which is coated with a matrix of anti-proliferative paclitaxel and a biocompatible excipient—enabling an optimal drug transfer to the target lesion tissue. An additional element, however, unique to Passeo-18 Lux, is the novel protective insertion aid to facilitate easier device introduction and handling.

“The release of Passeo-18 Lux is a significant advancement for both physicians and patients, as DRBs are emerging as a safe and durable therapy option for lower limb arterial disease,” commented Alain Aimonetti, Vice President of Sales and Business Development, BIOTRONIK Vascular Intervention. “Our significant investment in developing outstanding peripheral vascular devices, supported by clinical evidence, is translating into real clinical benefits.”

#### **About BIOTRONIK**

As one of the world’s leading manufacturers of cardio- and endovascular medical devices, BIOTRONIK is headquartered in Berlin, Germany, and represented in over 100 countries by its global workforce of more than 5600 employees. Several million heart patients around the world have received BIOTRONIK implants designed to save and improve the quality of their lives, or have been treated with BIOTRONIK coronary and peripheral vascular intervention products. Since its development of the first German pacemaker in 1963, BIOTRONIK has engineered many innovations—including BIOTRONIK Home Monitoring® in 2000, the world’s first 4F compatible 200mm peripheral stent, in 2010, Orsiro, the industry’s first hybrid drug-eluting stent, in 2011, and the world’s first implantable cardioverter-defibrillators and heart failure therapy devices with ProMRI® technology in 2012.

**For more information, visit:** [www.biotronik.com](http://www.biotronik.com)

#### **Contact:**

Manuela Schildwächter  
Global Communications Manager  
BIOTRONIK SE & Co. KG  
Woermannkehre 1  
12359 Berlin  
Tel. +49 (0) 30 68905 1466  
Email: [manuela.schildwaechter@biotronik.com](mailto:manuela.schildwaechter@biotronik.com)

**Upon publication, please provide us with a copy.**